DACTINOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C62H86N12O16
Molecular Weight	1255.4194
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)[C@]1([H])C(=O)N2CCC[C@@]2([H])C(=O)N(C)CC(=O)N(C)[C@@]([H])(C(C)C)C(=O)O[C@]([H])(C)[C@@]([H])(C(=N1)O)N=C(c3ccc(C)c4c3nc-5c(c(c(=O)c(C)c5o4)N)C(=N[C@@]6([H])[C@@]([H])(C)OC(=O)[C@]([H])(C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@@]([H])(C(C)C)N=C6O)O)O

InChI

InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N

InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C62H86N12O16
Molecular Weight	1255.4194
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954

Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 232 Target ID: CHEMBL2311221 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Binding Agent 996		156.25 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Wilms' tumor 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8043	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date -1.59667192E11
Childhood rhabdomyosarcoma 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8043	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date -1.59667192E11
Metastatic nonseminomatous testicular cancer 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8043	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date -1.59667192E11
Ewing’s sarcoma 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8043	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date -1.59667192E11
Gestational trophoblastic neoplasia 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8043	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date -1.59667192E11
Locally recurrent and locoregional sarcomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8043	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date -1.59667192E11
Locally recurrent and locoregional carcinomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8043	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date -1.59667192E11
Locally recurrent and locoregional adenocarcinomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8043	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date -1.59667192E11

C_max

Value	Dose	Co-administered	Analyte	Population
30.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
25.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931	1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered:		DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
142.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.67 μg × min/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931	1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered:		DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931	1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered:		DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	Other AEs: Pancytopenia, Mucositis... Other AEs: Pancytopenia (1 patient) Mucositis (severe, 1 patient) Pancreatitis (1 patient) Hyponatremia (1 patient) Hypocalcemia (1 patient) Respiratory distress (1 patient) Melena (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
0.15 ug/kg multiple, intravenous (total) Highest studied dose Dose: 0.15 ug/kg Route: intravenous Route: multiple Dose: 0.15 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/1139861	unhealthy, 40-77 years n = 2 Health Status: unhealthy Condition: malignant melanoma Age Group: 40-77 years Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/1139861	Sources: https://pubmed.ncbi.nlm.nih.gov/1139861
1.5 mg/m2 single, intravenous Highest studied dose Dose: 1.5 mg/m2 Route: intravenous Route: single Dose: 1.5 mg/m2 Sources: https://pubmed.ncbi.nlm.nih.gov/14522028	unknown, children n = 1 Health Status: unknown Age Group: children Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/14522028	Sources: https://pubmed.ncbi.nlm.nih.gov/14522028

AEs

AE	Significance	Dose	Population
Hypocalcemia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Hyponatremia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Melena	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Pancreatitis	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Pancytopenia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Respiratory distress	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Mucositis	severe, 1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579

Sourcing

Vendor/Aggregator	ID	URL
Achemtek	0104-058162	http://www.achemtek.com/50-76-0
Acorn PharmaTech	ACN-036884	http://www.acornpharmatech.com/
Ambinter	Amb19930304	http://www.ambinter.com/reference/19930304
Aurora Fine Chemicals LLC	A17.878.164	http://online.aurorafinechemicals.com/info?ID=A17.878.164
AvaChem Scientific	4693	http://www.avachem.com/productSearch.asp?4693
Avantor Inc	101096-738	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-738
Avantor Inc	200036-466	https://us.vwr.com/store/product/18601366/actinomycin-d
BOC Sciences	50-76-0	https://adc.bocsci.com/product/actinomycin-d-cas-50-76-0-1293.html
Chemspace	CSSB02125550997	https://chem-space.com/CSSB02125550997
Glentham Life Sciences	GA0481	http://www.glentham.com/products/product/GA0481/
OChem	10380	http://www.ocheminc.com/index.php?act=psearch&pid=050A760
Selleck Chemicals	S8964	http://www.selleckchem.com/products/actinomycin-d.html
Sigma-Aldrich	01815_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/01815?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A1410_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a1410?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A4262_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a4262?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A9415_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a9415?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1162400_USP	https://www.sigmaaldrich.com/catalog/product/usp/1162400?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S548606	http://www.smolecule.com/products/s548606
THE BioTek	bt-288011	https://www.thebiotek.com/product/inhibitors/bt-288011
VladaChem	VL272217-10MG	https://www.vladachem.com/product.php?products=50-76-0
abcr GmbH	AB353527	http://www.abcr.de/shop/en/AB353527
eNovation Chemicals	D371034	http://www.enovationchem.com/productDetails.asp?productID=D371034
iChemical	EBD32182	http://www.ichemical.com/products/50-76-0.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.	1999 Apr	10100995
Rapid nucleolytic degradation of the small cytoplasmic Y RNAs during apoptosis.	1999 Aug 27	10455152
Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme.	2000	10663630
Testin induction: the role of cyclic 3',5'-adenosine monophosphate/protein kinase A signaling in the regulation of basal and lonidamine-induced testin expression by rat sertoli cells.	2000 Dec	11090432
Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin--preliminary report about hepatoprotective effect of amifostine.	2000 May-Jun	11208352
Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients.	2000 Oct	11194540
Modification of biophysical properties of lung epithelial Na(+) channels by dexamethasone.	2000 Sep	10942727
Stimulation of cyclooxygenase-2-activity by nitric oxide-derived species in rat chondrocyte: lack of contribution to loss of cartilage anabolism.	2001 Apr 15	11286988
Nitric oxide suppresses the expression of Bcl-2 binding protein BNIP3 in hepatocytes.	2001 Dec 14	11592958
Transient posterior encephalopathy induced by chemotherapy in children.	2001 Feb	11275465
Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.	2001 Feb	11234897
The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts.	2001 Feb	11216681
Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells.	2001 Feb 1	11172741
Developmental reprogramming of rat GLUT-5 requires de novo mRNA and protein synthesis.	2001 Jan	11123204
Arsenic induces expression of the multidrug resistance-associated protein 2 (MRP2) gene in primary rat and human hepatocytes.	2001 Jul	11408547
Cadmium-induced cell transformation and tumorigenesis are associated with transcriptional activation of c-fos, c-jun, and c-myc proto-oncogenes: role of cellular calcium and reactive oxygen species.	2001 Jun	11353138
Differential induction of rat hepatic cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in response to pyridine treatment.	2001 Mar	11181506
Gene expression profile in BALB/c-3T3 cells transformed with beryllium sulfate.	2001 Sep	11568973
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.	2001 Sep 11	11535817
Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity.	2002 Jan 1	11756511
Identification of manganese superoxide dismutase as a NO-regulated gene in rat glomerular mesangial cells by 2D gel electrophoresis.	2003 Dec	14996425
Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.	2003 Jun	12807743
Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation.	2003 Mar	12663510
Differential expression of c-fos and c-myc protooncogenes by estrogens, xenobiotics and other growth-stimulatory agents in primary rat hepatocytes.	2003 Mar	12632255
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells.	2003 May 15	12704794
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis.	2003 Oct 3	12874281
Thyroid hormone activates fibroblast growth factor receptor-1 in bone.	2003 Sep	12805413
Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling.	2003 Sep 5	12927789
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.	2004 Dec	15610522
Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma.	2004 Dec	15591910
DEP-induced fra-1 expression correlates with a distinct activation of AP-1-dependent gene transcription in the lung.	2004 Feb	14565943
Mechanism of heme oxygenase-1 gene induction by quercetin in rat aortic smooth muscle cells.	2004 Jun	15118350
Endosulfan-mediated biochemical changes in the freshwater fish Clarias batrachus.	2004 Mar	15202864
Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues.	2004 Nov	15543019
2-Substituted benzoxazinone analogues as anti-human coronavirus (anti-HCoV) and ICAM-1 expression inhibition agents.	2004 Sep 20	15324901
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.	2005 Apr	15725475
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.	2005 Feb 10	15592511
Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells.	2005 Feb 25	15652504
Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells.	2005 Jan 1	15588712
Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver.	2005 Jan 14	15537571
Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists.	2005 Jan 28	15531761
Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression.	2005 Mar	15701621
Mitochondrial redox state regulates transcription of the nuclear-encoded mitochondrial protein manganese superoxide dismutase: a proposed adaptive response to mitochondrial redox imbalance.	2005 Mar 1	15683720
Promoting insulin secretion in pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors.	2005 May	15778011

Patents

Sample Use Guides

In Vivo Use Guide

Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.

Route of Administration: Intravenous

In Vitro Use Guide

Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:57:37 UTC 2021` Edited by `admin` on `Fri Jun 25 20:57:37 UTC 2021`
Record UNII	1CC1JFE158
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DACTINOMYCIN

Official Name

English

DACTINOMYCIN [HSDB]

Common Name

English

ACTINOMYCIN C1

Common Name

English

ACTINOMYCIN D [WHO-IP]

Common Name

English

DACTINOMYCIN [WHO-IP]

Common Name

English

3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-

Common Name

English

ACTINOMYCIN-D

Common Name

English

ACTINOMYCIN I1

Common Name

English

DILACTONE ACTINOMYCIN D ACID

Common Name

English

ACTINOMYCIN D [JAN]

Common Name

English

DACTINOMYCIN [USP-RS]

Common Name

English

GNF-PF-2290

Code

English

DACTINOMYCIN [USP MONOGRAPH]

Common Name

English

ACTINOMYCIN D [IARC]

Common Name

English

DACTINOMYCIN [MART.]

Common Name

English

DACTINOMYCIN [USAN]

Common Name

English

DACTINOMYCIN [VANDF]

Common Name

English

MERACTINOMYCIN

Common Name

English

ACTINOMYCIN X1

Common Name

English

DACTINOMYCINUM [WHO-IP LATIN]

Common Name

English

DACTINOMYCIN [MI]

Common Name

English

DACTINOMYCIN [ORANGE BOOK]

Common Name

English

DACTINOMYCIN [WHO-DD]

Common Name

English

N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE

Common Name

English

NSC-3053

Code

English

ACTINOMYCIN D

Common Name

English

NCI-C04682

Code

English

ACTINOMYCIN IV

Common Name

English

DACTINOMYCIN [INN]

Common Name

English

ONCOSTATIN K

Common Name

English

COSMEGEN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C204